FARSA

Across TCGA pan-cancer cohorts, FARSA mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FARSA data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher FARSA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FARSA expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and LSCC are the cancer types where FARSA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	1.000	0.895	.038	24	view →
PDAC	DFS	Median	II,III,IV	0.488	0.257	.003	13	view →
LSCC	DFS	Tertile	All	0.913	0.302	.004	10	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	8	view →
CCRCC	DFS	Tertile	IV	0.758	0.108	.024	6	view →
LUAD	OS	Median	II,III,IV	0.360	0.907	.008	3	view →
GBM	OS	Quartile	All	0.964	0.804	.031	1	view →
HNSC	DFS	Median	All	0.849	0.709	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FARSA–COAD (DFS)

Open the COAD breakdown →